WO2000056404B1 - Formulations for treatment of pain comprising vitamin b12 and phenylanine - Google Patents

Formulations for treatment of pain comprising vitamin b12 and phenylanine

Info

Publication number
WO2000056404B1
WO2000056404B1 PCT/GB2000/001092 GB0001092W WO0056404B1 WO 2000056404 B1 WO2000056404 B1 WO 2000056404B1 GB 0001092 W GB0001092 W GB 0001092W WO 0056404 B1 WO0056404 B1 WO 0056404B1
Authority
WO
WIPO (PCT)
Prior art keywords
pain
vitamin
page
treatment
renumbered
Prior art date
Application number
PCT/GB2000/001092
Other languages
French (fr)
Other versions
WO2000056404A1 (en
Inventor
David Frederick Horrobin
Original Assignee
Kilgowan Ltd
Horrobin David F
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Kilgowan Ltd, Horrobin David F filed Critical Kilgowan Ltd
Priority to AU33129/00A priority Critical patent/AU3312900A/en
Publication of WO2000056404A1 publication Critical patent/WO2000056404A1/en
Publication of WO2000056404B1 publication Critical patent/WO2000056404B1/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/02—Drugs for disorders of the nervous system for peripheral neuropathies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/06—Antimigraine agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Biomedical Technology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Neurology (AREA)
  • Engineering & Computer Science (AREA)
  • Organic Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Neurosurgery (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pain & Pain Management (AREA)
  • Psychiatry (AREA)
  • Molecular Biology (AREA)
  • Epidemiology (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

Orally administrable formulations containing a vitamin B12 component, preferably hydroxocobalamin, and phenylalanine are described. They may be taken at a specified daily dosage to provide 50 to 5000 mg phenylalanine per day and 0.2 to 50 mg of vitamin B12 component. They are used to treat pain or chronic fatigue syndrome. Other drugs or essentiel nutrients may be added such as folic acid, glucosamine or an anti-depressant drug as appropriate.

Claims

_ _
AMENDED CLAIMS
[received by the International Bureau on 27 September 2000 (27 09 00), original claim 10 cancelled, original claims 1 1 - 14 renumbered as 10-13 remaining claims unchanged ( 1 page)]
Claims and additionally containing folic acid or related bioactive derivative.
10. A method of treatment of pain or chronic fatigue syndrome which comprises the oral administration of a formulation in accordance of any one of the preceding Claims#
11. A method according to Claim 10 wherein the pain is diabetic pain due to peripheral nerve damage.
12. A method according to Claim 10 wherein the pain is a chest, abdominal, limb, pelvic, back or other pain originating from the spinal column.
13. A method according to Claim 10 wherein the pain is a headache or migraine headache.
STATEMENT UNDER ARTICLE 19
Old claim 10 has been deleted and subsequent claims renumbered. The impact of this on the text of the case will lead in due course to the cancellation of lines 3 to 5 on page 5 and of Examples 21 to 24 from page 6.
PCT/GB2000/001092 1999-03-24 2000-03-23 Formulations for treatment of pain comprising vitamin b12 and phenylanine WO2000056404A1 (en)

Priority Applications (1)

Application Number Priority Date Filing Date Title
AU33129/00A AU3312900A (en) 1999-03-24 2000-03-23 Formulations for treatment of pain comprising vitamin b12 and phenylanine

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
GBGB9906808.2A GB9906808D0 (en) 1999-03-24 1999-03-24 Formulation for treatment of pain
GB9906808.2 1999-03-24

Publications (2)

Publication Number Publication Date
WO2000056404A1 WO2000056404A1 (en) 2000-09-28
WO2000056404B1 true WO2000056404B1 (en) 2000-12-21

Family

ID=10850289

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/GB2000/001092 WO2000056404A1 (en) 1999-03-24 2000-03-23 Formulations for treatment of pain comprising vitamin b12 and phenylanine

Country Status (3)

Country Link
AU (1) AU3312900A (en)
GB (1) GB9906808D0 (en)
WO (1) WO2000056404A1 (en)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP7071754B2 (en) 2020-07-28 2022-05-19 株式会社東洋新薬 Joint function improving composition

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7232805B2 (en) 2003-09-10 2007-06-19 Inflabloc Pharmaceuticals, Inc. Cobalamin conjugates for anti-tumor therapy
JP5161472B2 (en) * 2007-03-30 2013-03-13 小林製薬株式会社 Analgesic composition
JP5241127B2 (en) * 2007-03-30 2013-07-17 小林製薬株式会社 Analgesic composition
EP2561879A1 (en) * 2011-08-23 2013-02-27 Protea Biopharma N.V. Macrophage activating factor for use in the treatment of chronic fatigue syndrome (CFS) and CFS-related diseases and disorders

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4331145A (en) * 1981-01-28 1982-05-25 Arthur Winter Multiple sclerosis treatment
GB2286528B (en) * 1994-02-17 1998-09-16 Robert John Woodward Dietary supplement
WO1996011009A1 (en) * 1994-10-05 1996-04-18 Cari Loder Treatment of multiple sclerosis (ms) and other demyelinating conditions using lofepramine in combination with l-phenylalanine, tyrosine or tryptophan and possibly a vitamin b12 compound
WO1998001157A1 (en) * 1996-07-05 1998-01-15 The Wwk Trust Compositions for the treatment of peripheral neuropathies containing antidepressants and/or monoamine oxidase inhibitors and/or vitamin b12 and/or precursors or inducers of a neurotransmitter
GB9617990D0 (en) * 1996-08-29 1996-10-09 Scotia Holdings Plc Treatment of pain
EP0835660A1 (en) * 1996-10-14 1998-04-15 Gaston Edmond Filomena Merckx Products containing methylcobalamin for the treatment of multiple sclerosis or other demyelinating conditions
DE19720818A1 (en) * 1996-11-15 1998-05-20 Sportmedizin Team Muenchen Arz Composition enhancing sports performance

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP7071754B2 (en) 2020-07-28 2022-05-19 株式会社東洋新薬 Joint function improving composition

Also Published As

Publication number Publication date
WO2000056404A1 (en) 2000-09-28
GB9906808D0 (en) 1999-05-19
AU3312900A (en) 2000-10-09

Similar Documents

Publication Publication Date Title
Gadangi et al. The anti-inflammatory mechanism of sulfasalazine is related to adenosine release at inflamed sites.
HK1072541A1 (en) Trans-epicutaneous administration form for treating restless leg syndrome
MXPA04006039A (en) Methods for the treatment of peripheral neural and vascular ailments.
NZ263736A (en) An inhibitor of stem cell proliferation for treating hyperproliferative conditions
AU677279B2 (en) Application of carbamazepine and oxcarbazepine in the treatment of Parkinson's disease and Parkinsonian syndromes
BG101118A (en) Therapeutical compounds
ES2191754T3 (en) PHENYL-DIHYDROBENZOFURANS.
AU5764496A (en) Cyclohexyl dihydrobenzofuranes
GR20000100153A (en) Articles of manufacture
EP0957925A4 (en) Treatment of osteoarthritis by administering poly-n-acetyl-d-glucosamine
WO2000056404B1 (en) Formulations for treatment of pain comprising vitamin b12 and phenylanine
IL135235A0 (en) Method and composition for preventing nephrotoxicity caused by cyclosporins and tacrolimus
WO2004014291B1 (en) Use of methylnaltrexone in treating gastrointestinal dysfunction in equines
WO2001080860A3 (en) Daily treatment for erectile dysfunction using a pde5 inhibitor
AU5634500A (en) Dietary calcium as a supplement to vitamin d compound treatment of multiple sclerosis
WO2001045715A3 (en) Combinations of an adenosine a1 agonist with an opioid and their use in the treatment of pain
WO2000053148A3 (en) Methods and compositions for treating erectile dysfunction
US20030194453A1 (en) Dietary supplement
WO2000056295A3 (en) Oral combinations of hydroxocobalamin and folic acid
AU2210297A (en) Nasal administration of agents for treatment of delayed onset emesis
WO2001005408A8 (en) Fat-binding polymers, optionally combined with lipase inhibitors
JP2002530327A5 (en)
EP0790250A3 (en) Inhibitors of biogenic amine transporters
WO2001028541A2 (en) Composition comprising sildenafil and l-arginine
WO2001028566B1 (en) Use of acetyl salicilyc acid for the treatment of benign prostate hyperplasia

Legal Events

Date Code Title Description
AK Designated states

Kind code of ref document: A1

Designated state(s): AU CA NZ US

AL Designated countries for regional patents

Kind code of ref document: A1

Designated state(s): AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE

121 Ep: the epo has been informed by wipo that ep was designated in this application
AK Designated states

Kind code of ref document: B1

Designated state(s): AU CA NZ US

AL Designated countries for regional patents

Kind code of ref document: B1

Designated state(s): AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE

B Later publication of amended claims
DFPE Request for preliminary examination filed prior to expiration of 19th month from priority date (pct application filed before 20040101)
WA Withdrawal of international application
WA Withdrawal of international application